skip to main content
Idioma:
Refinado por: assunto: Clinical Medicine remover Base de dados/Biblioteca: EBSCOhost Business Source Complete remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Pritchard-Jones, Kathy, Prof ; Bergeron, Christophe, MD ; de Camargo, Beatriz, MD ; van den Heuvel-Eibrink, Marry M, MD ; Acha, Tomas, MD ; Godzinski, Jan, MD ; Oldenburger, Foppe, MD ; Boccon-Gibod, Liliane, MD ; Leuschner, Ivo, Prof ; Vujanic, Gordan, Prof ; Sandstedt, Bengt, MD ; de Kraker, Jan, MD ; van Tinteren, Harm, PhD ; Graf, Norbert, MD

The Lancet (British edition), 2015-09, Vol.386 (9999), p.1156-1164 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.